Centogene N.V.

Equities

CNTG

NL0014040206

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.461 ^USD	-3.96%		-3.96%	-61.58%

Apr. 02	Centogene Gets Nasdaq Noncompliance Notice	MT
Mar. 19	Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	MT

Centogene N.V. Reports Earnings Results for the Full Year Ended December 31, 2021

March 31, 2022 at 02:08 pm EDT

Centogene N.V. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 189.92 million compared to EUR 128.38 million a year ago. Net loss was EUR 46.85 million compared to EUR 21.38 million a year ago.

Latest news about Centogene N.V.

Centogene Gets Nasdaq Noncompliance Notice	Apr. 02	MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	Mar. 19	MT
Centogene N.V. Announces the Extension of an Ongoing Partnership with Takeda to Continue Providing Access to Genetic Testing for Patients with Lysosomal Storage Disorders	Mar. 19	CI
Centogene Explores Strategic Alternatives	Feb. 27	CI
Centogene N.V. and the Laboratory of Human Genetics of Infectious Diseases At Institut Imagine Announce Rare Disease Research Collaboration	Jan. 25	CI
Centogene N.V. and The Michael J. Fox Foundation for Parkinson's Research Announces Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics	Jan. 23	CI
Centogene N.V. Provides Earnings Guidance for the Full Year 2023	Jan. 18	CI
Centogene N.V. Announces Changes to Supervisory Board	Dec. 18	CI
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone	Dec. 13	CI
Centogene, Saudi Arabia's Public Investment Fund Form JV	Nov. 28	MT
Centogene N.V. and Lifera Complete Strategic Joint Venture Transaction	Nov. 28	CI
Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism	Nov. 14	CI
Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering	23-10-10	CI
Flemming Ornskov Decides to Step Down from His Role as a Member of the Supervisory Board of Centogene	23-10-06	CI
Centogene N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-07	CI
Centogene N.V. Reaffirms Revenue Guidance for the Year 2023	23-09-07	CI
Upcoming Payrolls Report Lifts Exchange-Traded Funds, Equity Futures Premarket Friday	23-09-01	MT
Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients	23-09-01	CI
Centogene Receives Non-Compliance Notice From Nasdaq	23-09-01	MT
Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board	23-08-18	CI
Centogene Regains Compliance With Nasdaq Listing Rules	23-07-14	MT
Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort	23-07-12	CI
Centogene Teams Up With Lifera to Boost Access to Multiomic Testing in Saudi Arabia	23-07-03	MT
Centogene N.V. and Lifera Enter Strategic Collaboration to Increase Access to Leading Data-Driven Multiomic Testing	23-06-27	CI
Centogene N.V. announced that it expects to receive $30 million in funding from Lifera	23-06-26	CI

Chart Centogene N.V.

Duration

Period

More charts

Company Profile

Centogene N.V., is a commercial company. The company focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The company's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Company's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Centogene N.V.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4314 EUR

Average target price

1.378 EUR

Spread / Average Target

+219.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CENTOGENE N.V.	-61.58%	12.85M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.90%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research